These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33606875)

  • 21. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.
    Caceres SM; Malcolm KC; Taylor-Cousar JL; Nichols DP; Saavedra MT; Bratton DL; Moskowitz SM; Burns JL; Nick JA
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6851-60. PubMed ID: 25182651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in
    Moore JE; Millar BC; Ollman-Selinger M; Cambridge L
    Respir Care; 2021 Sep; 66(9):1446-1457. PubMed ID: 34031222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity of
    Vanderwoude J; Azimi S; Read TD; Diggle SP
    mBio; 2024 Feb; 15(2):e0310923. PubMed ID: 38171021
    [No Abstract]   [Full Text] [Related]  

  • 26. Pseudomonas aeruginosa Isolates From a Cohort of Mexican Children With Cystic Fibrosis Show Adaptation to a Chronic Phenotype.
    Rosales-Reyes R; Rodríguez-Alvarado M; Lezana-Fernández JL; Sánchez-Lozano JY; Gayosso-Vázquez C; Jarillo-Quijada MD; Toledano-Tableros JE; Arredondo-Mercado MJ; Alcántar-Curiel MD; Lincopan N; Vidal JE; Lascurain R; Valvano MA; Santos-Preciado JI
    Pediatr Infect Dis J; 2020 Oct; 39(10):899-906. PubMed ID: 32453200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Van Stormbroek B; Zampoli M; Morrow BM
    Pediatr Pulmonol; 2019 Apr; 54(4):393-398. PubMed ID: 30656856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
    Ratjen F; Döring G; Nikolaizik WH
    Lancet; 2001 Sep; 358(9286):983-4. PubMed ID: 11583754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates.
    Tramper-Stranders GA; van der Ent CK; Molin S; Yang L; Hansen SK; Rau MH; Ciofu O; Johansen HK; Wolfs TF
    Clin Microbiol Infect; 2012 Jun; 18(6):567-74. PubMed ID: 21883670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.
    Mayer-Hamblett N; Ramsey BW; Kulasekara HD; Wolter DJ; Houston LS; Pope CE; Kulasekara BR; Armbruster CR; Burns JL; Retsch-Bogart G; Rosenfeld M; Gibson RL; Miller SI; Khan U; Hoffman LR
    Clin Infect Dis; 2014 Sep; 59(5):624-31. PubMed ID: 24863401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis.
    Sunman B; Emiralioglu N; Hazirolan G; Şener B; Ozsezen B; Tural DA; Buyuksahin HN; Guzelkas I; Yalcin E; Dogru D; Özçelik U; Kiper N
    Pediatr Pulmonol; 2022 Jun; 57(6):1456-1465. PubMed ID: 35229497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
    McCaughey G; Diamond P; Elborn JS; McKevitt M; Tunney MM
    PLoS One; 2013; 8(7):e69763. PubMed ID: 23936095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Three Eradication Treatment Protocols for Pseudomonas Aeruginosa in Children and Adolescents with Cystic Fibrosis.
    Schütz K; Grewendorf S; Kontsendorn J; Fuge J; Happle C; Rudolf I; Dopfer C; Sedlacek L; Hansen G; Junge S; Dittrich AM
    Klin Padiatr; 2023 Mar; 235(2):75-83. PubMed ID: 36758577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scorpionfish BPI is highly active against multiple drug-resistant
    Holzinger JM; Toelge M; Werner M; Ederer KU; Siegmund HI; Peterhoff D; Blaas SH; Gisch N; Brochhausen C; Gessner A; Bülow S
    Elife; 2023 Jul; 12():. PubMed ID: 37461324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis.
    Blanchard AC; Horton E; Stanojevic S; Taylor L; Waters V; Ratjen F
    J Cyst Fibros; 2017 May; 16(3):395-400. PubMed ID: 28189634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
    Fitzpatrick SB; Rosenstein BJ
    Clin Pediatr (Phila); 1983 Sep; 22(9):628-30. PubMed ID: 6224623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Wood DM; Smyth AR
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004197. PubMed ID: 16437476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.